Global Markets Direct's, 'Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinopathy. Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global therapeutic scenario for Retinopathy.
- A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinopathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:
Table of Contents
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Retinopathy Overview
Therapeutics Development
Pipeline Products for Retinopathy - Overview
Pipeline Products for Retinopathy - Comparative Analysis
Retinopathy - Therapeutics under Development by Companies
Retinopathy - Therapeutics under Investigation by Universities/Institutes
Retinopathy - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Retinopathy - Products under Development by Companies
Retinopathy - Products under Investigation by Universities/Institutes
Retinopathy - Companies Involved in Therapeutics Development
GTx, Inc.
Affichem
SIFI S.p.A
TWi Pharmaceuticals, Inc.
Retinopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Drug Profiles
interferon gamma-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AC-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Beta-LGND2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mutants Of Pigment Epithelium Derived Factor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AF-243 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinopathy - Dormant Projects
Retinopathy - Discontinued Products
Retinopathy - Product Development Milestones
Featured News & Press Releases
May 08, 2012: Gene Signal Presents Preclinical Data Of Aganirsen At ARVO Annual Meeting
Mar 19, 2012: QLT Receives Orphan Drug Designation For Visudyne For Treatment of Central Serous Chorioretinopathy
Feb 14, 2012: Gene Signal And Collaborators Demonstrate Successful Activity Of Topical Aganirsen In Models Of Retinal Neovascular Disease
Appendix
Methodology
Coverage
Secondary Research
List of Tables
Number of Products under Development for Retinopathy, H2 2013
Number of Products under Development for Retinopathy - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Clinical Stage Development, H2 2013
Comparative Analysis by Early Stage Development, H2 2013
Comparative Analysis by Unknown Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Retinopathy - Pipeline by GTx, Inc., H2 2013
Retinopathy - Pipeline by Affichem, H2 2013
Retinopathy - Pipeline by SIFI S.p.A, H2 2013
Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Number of Products by Stage and Target, H2 2013
Number of Products by Stage and Mechanism of Action, H2 2013
Number of Products by Stage and Route of Administration, H2 2013
Number of Products by Stage and Molecule Type, H2 2013
Number of Products by Stage and Therapeutic Class, H2 2013
Retinopathy - Dormant Projects, H2 2013
Retinopathy - Discontinued Products, H2 2013

List of Figures
Number of Products under Development for Retinopathy, H2 2013
Number of Products under Development for Retinopathy - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Early Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Number of Products by Top 10 Target, H2 2013
Number of Products by Stage and Top 10 Target, H2 2013
Number of Products by Top 10 Mechanism of Action, H2 2013
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013
Number of Products by Top 10 Route of Administration, H2 2013
Number of Products by Stage and Top 10 Route of Administration, H2 2013
Number of Products by Top 10 Molecule Type, H2 2013
Number of Products by Stage and Top 10 Molecule Type, H2 2013
Number of Products by Top 10 Therapeutic Class, H2 2013
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2734063/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Retinopathy - Pipeline Review, H2 2013
Web Address: http://www.researchandmarkets.com/reports/2734063/
Office Code: SCD2VV96

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>☐ USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>☐ USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>☐ USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World